{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
tyrosine
to a specific field?
Status:
Investigational
Source:
NCT03700294: Phase 1 Interventional Terminated Advanced Solid Tumors
(2018)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03541369: Phase 1 Interventional Terminated Relapsed/Refractory Acute Myeloid Leukemia (AML)
(2018)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT02890368: Phase 1 Interventional Terminated Solid Tumors
(2016)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT02665065: Phase 3 Interventional Active, not recruiting Acute Myeloid Leukemia
(2016)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:runimotamab [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT02988817: Phase 1/Phase 2 Interventional Completed Ovarian Cancer
(2016)
Source URL:
Class:
PROTEIN
Status:
Investigational
Class:
PROTEIN
Status:
Investigational
Source:
NCT03855852: Not Applicable Interventional Unknown status Bone Loss, Alveolar
(2019)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:trastuzumab envedotin [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT02544438: Phase 1/Phase 2 Interventional Completed Acute Myeloid Leukemia
(2015)
Source URL:
Class:
PROTEIN
